12 trends tracked about this subject — the full history, oldest to newest below.
Bristol Myers Squibb reports successful Phase 2 results for its next-generation GPRC5D-directed CAR-T therapy targeting heavily treated myeloma patients.
Bristol Myers Squibb stock rises as its blood cancer cell therapy succeeds in a mid-stage trial.
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The FDA has granted accelerated approval to Bristol Myers Squibb's Zenbexus, introducing a novel CELMoD drug class for multiple myeloma treatment.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pharmaceutical leader Bristol Myers Squibb is investing $2.3 billion to establish a massive new manufacturing campus in Houston, Texas.
Analysts express perplexity as reports indicate active merger talks between Bristol-Myers Squibb and AstraZeneca.
AstraZeneca shares have declined following reports of potential $400 billion merger talks with Bristol Myers Squibb.
Bristol Myers Squibb is partnering with Nvidia to construct what it claims will be the most powerful AI supercomputer in the pharmaceutical industry.
A US House committee has launched an investigation into major pharmaceutical companies regarding the use of clinical trial sites in China.